"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM

I-SPY Email List Sign-up

Featured News

Upcoming FDA workshop: "Clinical Trials to Optimize Outcomes in Early Breast Cancer"

Announcement

September 14, 2018

I-SPY 2, an Innovative Clinical Trial Model that is Revolutionizing the Treatment of Early Stage, High-Risk Breast Cancer

Press Release

September 12, 2018

Advanced MRI methods tested in I-SPY 2 may improve monitoring and prediction of treatment response

Announcement

September 7, 2018

-- more news --

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.

1300

patients enrolled

16

agents completed
evaluation since 2010

3

agents received
accelerated approval

World-class science requires world-class scientists

Meet some of our team

Diane Heditsian

Investigators, Patient Advocate, CEO, deClarity Life Sciences, UCSF Breast Science Advocacy

Andres Forero-Torres

Professor of Medicine

University of Alabama at Birmingham

Kathleen Kemmer

Medical Oncologist

Oregon Health and Science University

Bioinformatician

University of California, San Francisco

Don't miss a thing! Get I-SPY results, news and event information delivered right to your inbox.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

I-SPY is supported by:

I-SPY Sponsor:
‍

Quantum Leap Healthcare Collaborative